Furthermore, reduced brain inflammation following treatment of MS patients with Daclizumab (an antagonistic humanized mAb against the IL-2Rα chain) correlated with an expansion of CD56bright NK cells and a reduction in CD4+ and CD8+ T cells in vivo[61]. This evidence concerns the gene IL2RA and myeloid sarcoma.